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ARTICLE
Robust continuous in vitro culture of the
Plasmodium cynomolgi erythrocytic stages
Adeline C.Y. Chua1,2,3,18, Jessica Jie Ying Ong2,3,18, Benoit Malleret 1,4, Rossarin Suwanarusk1,2,
Varakorn Kosaisavee4,5, Anne-Marie Zeeman6, Caitlin A. Cooper7, Kevin S.W. Tan 4, Rou Zhang4,
Bee Huat Tan3, Siti Nurdiana Abas3, Andy Yip3, Anne Elliot7, Chester J. Joyner8,9, Jee Sun Cho4, Kate Breyer10,
Szczepan Baran 10, Amber Lange10, Steven P. Maher 7, François Nosten 11,12, Christophe Bodenreider3,
Bryan K.S. Yeung3, Dominique Mazier13,14, Mary R. Galinski9,15, Nathalie Dereuddre-Bosquet16,
Roger Le Grand16, Clemens H.M. Kocken6, Laurent Rénia 1,4, Dennis E. Kyle 7, Thierry T. Diagana3,
Georges Snounou13,14,16, Bruce Russell 2 & Pablo Bifani 1,3,4,17
The ability to culture pathogenic organisms substantially enhances the quest for fundamental
knowledge and the development of vaccines and drugs. Thus, the elaboration of a protocol for
the in vitro cultivation of the erythrocytic stages of Plasmodium falciparum revolutionized
research on this important parasite. However, for P. vivax, the most widely distributed and
difﬁcult to treat malaria parasite, a strict preference for reticulocytes thwarts efforts to
maintain it in vitro. Cultivation of P. cynomolgi, a macaque-infecting species phylogenetically
close to P. vivax, was brieﬂy reported in the early 1980s, but not pursued further. Here, we
deﬁne the conditions under which P. cynomolgi can be adapted to long term in vitro culture to
yield parasites that share many of the morphological and phenotypic features of P. vivax. We
further validate the potential of this culture system for high-throughput screening to prime
and accelerate anti-P. vivax drug discovery efforts.
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The development of a protocol for the routine continuousin vitro culture of Plasmodium falciparum in 19761released malaria researcher from the reliance on in vivo
observations. This led to the major fundamental and translational
advances in all aspects of the life cycle of this parasite that is
responsible for the highest mortality rates globally. Recent
recognition that the widespread species P. vivax causes substantial
morbidity2 made it imperative to devise efﬁcient means to control
it. Furthermore, effective measures that could lead to its elim-
ination would require the development of novel drugs to elim-
inate the hypnozoite, the dormant liver form responsible for
relapses that also characterise P. vivax infections, as well as
strategies to thwart transmission. However, research on P. vivax
remains severely hampered because, to date, attempts to maintain
this parasite in routine in vitro blood cultures have been hindered
by the strict restriction to invasion of reticulocytes, a minor short-
lived fraction of peripheral blood. Historically, a parasite of
Southeast Asian macaques, P. cynomolgi, has been used as the
favoured model for P. vivax. The remarkable morphological and
biological similarities between these two parasite species are now
known to extend to their genetic make-up3,4. The hepatic stages
of malaria parasites were ﬁrst discovered using P. cynomolgi5 as
was the hypnozoite5–7. Indeed, P. cynomolgi was central to
the development of primaquine8 and remains so in the search
for novel anti-relapse compounds both in experimental infec-
tions9,10 and as a basis for the recently developed in vitro-
cultured hypnozoite model11–13.
In the last decade, high-throughput screens based on cultured
P. falciparum or on those of the hepatic stages of the rodent
parasites P. berghei or P. yoelii, as reviewed in Hovlid and Win-
zeler14, have enriched the drug discovery pipeline with a wealth of
promising novel lead compounds. However, such screening
strategies are precluded for P. vivax because of the limited
availability of infected blood from patients, an obstacle that would
be circumvented should in vitro-cultured P. cynomolgi be avail-
able. There were two reports of continuous in vitro culture of the
blood stages of two strains of P. cynomolgi (Berok in one, and
Vietnam in the other) in the early 1980’s15,16. Given the regular
and onerous use of P. cynomolgi in macaques for biological and
drug discovery programmes, it was surprising that these early
observations were not exploited further.
Following careful assessment of various culture conditions, we
describe here the robust continuous cultivation of the blood
stages of P. cynomolgi lines derived from the Berok strain. We
show that the in vitro-cultured P. cynomolgi (from ex vivo or
cryopreserved stocks) retain the key characteristics that these
parasites share with P. vivax. We further demonstrate that these
parasites are suitable for high-throughput screening for anti-
malarial compounds.
Results
Propagation of P. cynomolgi strains. Three P. cynomolgi lines
were available to us: the Berok strain cryopreserved in 2003 from
Aotus trivirgatus (initially isolated in 1964), the B strain
(P. cynomolgi bastianelli, initially isolated in 1959) and the M
strain (P. cynomolgi Mulligan strain ﬁrst isolated in the 1930s).
Separate Macaca fascicularis monkeys were successfully infected
with one or other of these lines (see the Methods section),
and blood samples were collected to initiate cultures. We con-
ducted preliminary experiments using the Berok strain, to test
various culture conditions, media and materials in short-term
cultures initiated from cryopreserved stocks prepared from
infected monkey blood (Fig. 1a). This allowed us to deﬁne an
optimal working protocol that was then tested on Berok strain
parasites from different animals, and on B and M strain parasites
freshly collected from infected macaques. Blood was collected
when most parasites were mature (late trophozoites and schi-
zonts), and depleted of leucocytes before enrichment of the mature
parasites on a Percoll gradient. In vitro cultures were initiated at
parasitaemia > 1% (50,000 parasites/µL) and monitored daily by
microscopic examination of Giemsa-stained smears. In repeated
independent experiments, the parasitaemia of the B and M strain
cultures declined to become undetectable within a few days
(Fig. 1b). By contrast, erythrocyte invasion was observed in the
cultures initiated with the Berok strain obtained from different
monkeys (K2, K3 and K4). Nonetheless, the multiplication rates of
the K2-initiated and K3-initiated cultures were low by comparison
with that of the K4-derived parasites. Thus, we opted to continue
subsequent work with the K4 culture. This initial Berok K4 line
culture, had a multiplication rate ranging from twofold to fourfold
over more than ﬁve cycles, such that regular dilution of the culture
became necessary. The K4 line was used to constitute working
cryopreserved stocks to conduct the studies described below.
Biological characteristics of in vitro-cultured Berok K4. Suc-
cessful propagation of the Berok K4 line was maintained for up to
180 days in cultures initiated with thawed parasites. Culture
conditions were further reﬁned, with robust growth best observed
under reduced oxygen environment (5% CO2, 5% O2 and 90%
N2) to reach parasitaemias beyond 10% (Fig. 1c). Growth rates
were unaffected by ﬂask conﬁguration (24-well plate, six-well
plate, T25 or T75 ﬂasks). Successful in vitro maintenance of the
Berok K4 stabilates was obtained independently in six additional
laboratories (the National University of Singapore, the University
of Otago in New Zealand, the University of Malaya in Malaysia,
the Shoklo Malaria Research Unit in Thailand, the Novartis
Institute for Tropical Diseases, Emeryville, California and at the
Université Pierre et Marie Curie in France). Genotyping of the
reticulocyte binding protein gene complex, whose types and copy
number vary between strains3,17–19, conﬁrmed that the K4 line
parasites were indeed derived from the original Berok stock
(Supplementary Fig. 1). The morphology of the parasites sampled
at 2 hourly intervals for 48 h (Fig. 1d) was indistinguishable from
that observed or previously described from infected animals, with
eight to sixteen merozoites observed in fully matured schizonts
around 46–48 h. Although macrogametocytes and micro-
gametocytes were intermittently observed from day 6 on, their
levels remained low and did not exceed 0.01% gametocytaemia.
Culture condition modiﬁcations that would lead to the higher
sexual stage production in vitro are currently being tested.
In vitro-cultured Berok K4 line retains transmission ability. In
vitro-cultured Berok K4 line parasites were used successfully to
infect a naive intact M. mulatta monkey, where asexual and
sexual stages were observed 6 days post infection (dpi) and
thereafter. Anopheles stephensi mosquitoes fed on infected blood
collected at 11 and 12 dpi (0.85% and 1.4% parasitaemia,
respectively) showed oocysts a week later (feed 11 dpi: in 40% of
mosquitoes, average of 3.5 oocysts/mosquito; feed 12 dpi: in 90%
of mosquitoes, average of 37.6 oocysts/mosquito). Eighteen days
after feeding, lots of 100,000 sporozoites isolated from salivary
glands (feed 12 dpi: ca. 31,000 sporozoites per mosquito) were
successfully used to infect two naive M. mulatta monkeys by
intravenous inoculation (Fig. 2a), and the course of the infections
was monitored by microscopy. Both monkeys became patent
11 dpi, and were later administered a 5-days chloroquine regimen
to eliminate blood-stage parasites in order to monitor for relapses
as previously described20. Monkey 1 relapsed 31 dpi and 52 dpi,
after which radical cure was administered (chloroquine and pri-
maquine), while the second remained negative for the whole
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Fig. 1 Adaptation of P. cynomolgi Berok K4 line to continuous culture. a Schematic diagram of the successful adaptation of P. cynomolgi (Berok) from in vivo
to in vitro culture. b Pilot ex vivo culture of P. cynomolgi Berok, B and M strain. The in vitro-cultured Berok K4 had to be sub-cultured at days 1, 3 and 5 due
to robust growth, in contrast to the M and B strains where parasitaemias decreased to undetectable levels after day 3. c P. cynomolgi (Berok) in vitro
culturing was further optimised to enable substantial multiplication (up to tenfold increase) that necessitated frequent dilution of the cultures when high
parasitaemias were reached (red arrowheads). d Mature schizonts of culture adapted P. cynomolgi Berok K4 were enriched and allowed to re-invade fresh
red blood cells that were then monitored every 2 h to document the complete asexual erythrocytic cycle in vitro. Scale bar represents 5 μm
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duration of follow-up (102 dpi). The time to patency was similar
to that noted for P. cynomolgi M strain infections (using the same
sporozoites inoculum and infection route), as was that for the ﬁrst
relapse (around day 27.5 ± 3.25 dpi in eight monkeys infected by
the M strain20). Usually, monkeys infected with P. cynomolgi M
strain relapse at least once, regardless of inoculation dose, which
contrasted with the relapse episodes noted in only one of two
rhesus monkeys inoculated with the P. cynomolgi Berok
K4 sporozoites. Sporozoites were also used to infect in vitro-
cultured M. mulatta primary hepatocytes, as previously descri-
bed11, and 6 days later schizonts and uninucleate parasites
(possibly hypnozoites) were detectable (Fig. 2b). The average
infectivity of the sporozoites derived from the P. cynomolgi Berok
K4 line was lower, around 16 pre-erythrocytic (PE) forms per
10,000 inoculated sporozoites, than that of those derived from the
P. cynomolgi M strain, around 23 PE forms per 10,000 inoculated
sporozoites (Fig. 2c). Enumeration of the two hepatic forms
suggested that the P. cynomolgi Berok K4 line generated half the
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number of hypnozoites (around 30%) compared with that pro-
duced by the P. cynomolgi M strain (around 60%) (Fig. 2d).
Further studies are required to ascertain whether the failure of
one of the monkeys infected with the Berok K4 line to relapse
within the 102-day observation period reﬂects the lower numbers
of uninucleate forms observed in vitro, or to a delayed relapse
pattern where the ﬁrst relapse occurs many months after spor-
ozoite inoculation, or to residual chloroquine that might have
suppressed a ﬁrst relapse.
Nanostructure and rheology of Berok K4 line-infected RBCs.
P. cynomolgi Berok K4 dramatically alters the nanostructural and
rheological properties of the infected red blood cell (iRBC) in a
manner similar to that observed for P. vivax. Caveolae (~90 nm-
diameter openings) appear on the surface of the infected RBC’s
(Supplementary Fig. 2). While these caveolae, which are generally
associated with vesicle complexes, have the same dimensions as
those noted in P. vivax, these are present in signiﬁcantly lesser
densities (Fig. 3a–d), our data on caveolae agree with previous in-
depth analyses conducted on P. cynomolgi Berok21. The
P. cynomolgi Berok K4-infected RBC increases in size with
maturation (rings ~5 µm and schizonts ~8 µm) with rosettes
forming ~20 h post invasion (Fig. 3e, f), a timeline similar to that
previously noted for P. vivax22. It is interesting that rosettes had
not been observed in earlier studies on the B and M strains23. The
P. cynomolgi Berok K4 rosettes formed highly stable adhesive
bonds requiring around 400 pN (piconewton) to affect a
separation (Fig. 3g, h), an adhesive force similar to that recorded
for P. vivax24.
High-throughput drug susceptibility assay using the Berok K4
line. We opted to validate the SYBR green I proliferation assay14,25
for use with the P. cynomolgi Berok K4 line, because it is used
routinely for anti-P. falciparum drug screening, to establish dose
response and single-point screens based on 96- and 384-well-plate
assay formats (Fig. 4a–c). Using the BioTek Synergy™ 4 hybrid
microplate reader, the range of the 72 h ﬂuorescent read-out in the
SYBR green I proliferation assay showed a linear correlation with
parasitaemia in the range of 0.3–2%. Culture medium was sup-
plemented with 20% macaque (Mf) serum for the Berok K4 line,
whereas the routine 0.5% AlbuMAX was used for P. falciparum.
Nonetheless, Z’ prime values from the average of 16 DMSO wells
(negative control) and 16 meﬂoquine wells (positive control) ran-
ged from 0.8 to 0.9 (Supplementary Fig. 3). In order to minimise
the use of materials from naive macaques for culture, initial
parasitaemia of 0.5 and 2% were chosen. A SYBR green I pro-
liferation assay was performed in a 384-well-plate format using a
set of reference compounds and selected compounds from the
Malaria Box (Medicines for Malaria Venture, Switzerland) (Fig. 4a,
b). The reference compounds included the licensed antimalarials
chloroquine, lumefantrine, pyrimethamine, artemisinin, atova-
quone and artesunate, as well as three drug candidates: the
phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor KDU691, the
imidazolopiperazines KAF179 and the spiroindolone KAF246
(KAF179 and KAF246 are analogues to KAF156 and KAE609
currently in phase 2b clinical trials26). The IC50 values measured for
both species were broadly concordant, though P. cynomolgi proved
more sensitive to artesunate, artemisinin and atovaquone (Fig. 4a).
The assay was also conducted for 38 in-house synthesised com-
pounds from the Malaria Box (Fig. 4b), and identiﬁed compounds
that had differential inhibitory activity against the two parasites
species. For example, MMV000563, MMV007839 and
MMV008294 were highly active against P. falciparum, but not P.
cynomolgi.
In order to evaluate whether the type of culture supplement
(serum or AlbuMAX) inﬂuences inhibitory activity, the Pathogen
Box chemical library (Medicines for Malaria Venture, Switzer-
land) was screened in a 384-well format as a single-point assay at
10 µM (Supplementary Fig. 4) using P. cynomolgi (20% Mf serum)
or P. falciparum (20% human serum or 0.5% AlbuMAX). The
Pathogen Box comprises 400 compounds, of which 125 are
antimalarial tool–compounds, 26 are reference compounds while
the rest include compounds active against tuberculosis (n= 116),
kinetoplastids (n= 70), helminths (n= 32), cryptosporidiosis
(n= 11), toxoplasmosis (n= 15) and dengue (n= 5) (http://
www.pathogenbox.org/). Assay data for P. cynomolgi in 20% Mf
serum (Column A) proved to be highly comparable with that
obtained for P. falciparum in 20% human serum (Column B), but
both assays differed signiﬁcantly from the P. falciparum assay
performed in 0.5% AlbuMAX (Column C). This observation was
not surprising given the high protein content of 20% serum-
supplemented media with the likely consequent effect on protein
binding. As above, the rate of inhibition of nine antimalarial
compounds (MMV676380, MMV023388, MMV026550,
MMV007625, MMV023949, MMV007638, MMV676442,
MMV006833 and MMV020289) were signiﬁcantly different for
both parasite species in the presence of 20% serum (Fig. 4c).
Overall, the SYBR green I proliferation assay demonstrated robust
reproducibility, at single point and for dose response, for both
Plasmodium species in serum-supplemented cultures.
Schizont maturation assays in the Berok K4 line and P. vivax.
Cultured P. cynomolgi is to be ultimately used as a surrogate for
P. vivax in drug sensitivity assays. Therefore, we carried out the
standard schizont maturation assay for P. vivax, using tightly syn-
chronised Berok K4 ring-stage cultures as well as several clinical
P. vivax isolates. The parasites were seeded on plates containing
serially diluted chloroquine and parasite development was assessed
about 44 h later by ﬂow cytometry (Fig. 5a). In parallel, the SYBR
green I proliferation assay was carried out for the same drug using
Fig. 2 Transmission study from P. cynomolgi Berok K4 continuous culture. a In vivo blood-stage parasitaemia in two rhesus monkeys infected with 100,000
P. cynomolgi Berok K4 sporozoites (because of the use of a log scale for parasitaemia, negative smears are shown as 0.0001% parasitaemia). Both
monkeys became blood-stage patent on day 11 post infection (dpi). Arrows indicate drug treatment (black arrows: 5-day chloroquine treatment, red arrow:
7-day primaquine treatment). Monkey 1 was bled for stocks on day 15, and relapsed (measured as thin smear positivity) on days 31 and 52, after which it
was treated with chloroquine and primaquine. Monkey 2 was bled on day 19 dpi, and did not relapse during the follow-up period of 102 dpi, after which it
was treated with primaquine. b In vitro infection of primary rhesus hepatocytes with P. cynomolgi Berok K4 sporozoites produced both hypnozoites (left
panel) and developing liver-stage schizonts (right panel). Cultures were ﬁxed at day 6 dpi, and stained with anti-PcHsp70 and a secondary antibody
labelled with Alexa 568 ﬂuorescent dye. Nuclei were stained with DAPI. An average of 16 PE forms per 10,000 inoculated P. cynomolgi Berok
K4 sporozoites were observed. Scale bar represents 50 μm. c The total PE forms of in vitro infection rate of various primary rhesus hepatocytes with
P. cynomolgi M strain sporozoites and P. cynomolgi Berok K4 line sporozoites. d The percentage of hypnozoites observed in vitro using primary rhesus
hepatocytes from different donors infected with P. cynomolgi M strain or P. cynomolgi Berok K4 line sporozoites. The data (c and d) were analysed using the
Welch’s t test with the signiﬁcance level set at P < 0.05. The histograms represent means (n= 3), and the error bars the standard error of the mean (SEM)
of replicates
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the Berok K4 line. Each dot represents individual P. vivax clinical
isolates and replicates for the Berok K4 line, respectively. The IC50
values for chloroquine were similar for P. cynomolgi in both assays
(Fig. 5b, c), and equally comparable with the IC50 values (~50 nM)
obtained from the P. vivax clinical isolates (Fig. 5d).
Discussion
The control of the globally distributed Plasmodium vivax became,
over the last decade, a priority for the malaria community.
Indeed, the biological characteristics that distinguish this species
from P. falciparum, in particular the propensity to relapse and its
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consequences and the increased vectorial capacity, are a sig-
niﬁcant challenge to current elimination efforts27. Moreover, the
increasing reports of resistance to chloroquine and the lack of an
anti-hypnozoite drug that could be mass-deployed have made it a
priority to seek novel compounds active against this parasite.
Furthermore, efforts to develop a vaccine against P. vivax sig-
niﬁcantly lag behind those devoted against P. falciparum. The
inability to culture P. vivax in the laboratory has in equal mea-
sures thwarted efforts to conduct functional studies and to screen
for novel lead compounds targeting P. vivax. Thus, investigations
of all aspects of P. vivax and the infection it causes are restricted
to ﬁeld and clinical observations, and to the few samples that can
be obtained from patients prior to treatment. The high cost and
ethical limitations inherent to the use of primate models, P. vivax
lines adapted to New World non-human primates, or P. cyno-
molgi in macaques, further constrain the scope of any investiga-
tions. The availability of in vitro-cultured P. cynomolgi makes this
suitable model for P. vivax available to a broad range of
researchers and opens the way to apply genetic manipulation
technologies that are as yet precluded for P. vivax.
The ﬁrst protocol for in vitro cultivation of the erythrocytic
stages of malaria parasite was made for P. falciparum and P. vivax
in 191228, though growth was restricted to a few cycles. Sustained
multiplication over extended periods (months), i.e., continuous
cultures, proved elusive and was ﬁnally achieved only in 1976 for
P. falciparum 1,29 after sustained efforts spanning three decades.
Within a few years, the continuous cultivation of four macaque
parasite species, P. knowlesi, P. cynomolgi, P. inui and P. fragile
were reported30. Whereas cultures of P. knowlesi were later
exploited to conduct genetic and biological studies31,32, none
appear to have been similarly employed for P. cynomolgi, despite
the evident beneﬁts that this could have provided over the years
to researchers investigating P. vivax. The fastidious testing of
culture conditions that we carried out and our subsequent
observations on the inability of some strains to grow in culture
might in part explain this gap. Human serum to supplement the
culture medium (successfully used in the initial publication from
1981) proved unsuitable in our hands, despite testing of numer-
ous batches. Moreover, though collected from naive animals, then
prepared and stored in a standard manner, the serum and in
some cases the red blood cells collected from only some but not
all naive M. fascicularis proved suitable for sustained parasite
multiplication.
It is not clear at present why establishment in vitro under the
adopted standard conditions appears to be limited to the Berok
line (the P. cynomolgi M or B strains failed to thrive, despite
numerous attempts). This phenomenon is not novel or peculiar
to P. cynomolgi, as similar variable success in adapting ﬁeld-
collected P. falciparum isolates has long been observed. The
successful adaptation to in vitro culture remains elusive and
multifaceted. It is well documented that the rbp genes are dif-
ferent in the various strains of P. cynomolgi3,17. It will be useful to
explore whether the fact that only the Berok strain, but neither
the B nor M strain, possesses the rbp1b gene played a role. This
gene is present in P. vivax3 though this species remains unculti-
vatable in vitro. Clearly, the mechanisms of merozoite invasion
are complex, and will require detailed investigations. Moreover,
red blood cell tropism might have played a role. In a recent study
by Kosaisavee et al.33, the P. cynomolgi B strain equally invaded
all types of monkey erythrocytes, while it was restricted to Duffy-
positive human reticulocytes.
The Berok strain, initially derived from a wild M. nemestrina
collected in peninsular Malaysia in the early 1960s, was main-
tained thereafter by blood and/or sporozoite inoculation pri-
marily in M. mulatta and later also in Aotus monkeys34. This
strain has not been cloned, and it is possible that it might harbour
diverse parasite genotypes which could vary in their proportion
over the course of infection and or in different hosts. It is at
present unknown whether the derived Berok parasites collected
from the various monkeys (K2–K4) differed in the proportion of
parasites that can rapidly adapt to thrive in culture, possibly as
genetically distinct lines from an otherwise heterogeneous
P. cynomolgi population, or as phenotypic variants selected from
an otherwise homogeneous population. Elucidation of the
molecular basis for this differential growth could provide fun-
damental insights on the biology of blood-stage parasites. It is
likely that lines from other P. cynomolgi isolates and strains, or
indeed from those of other macaque parasite species, would also
be amenable to blood-stage cultivation, provided that the initial
failures are met with perseverance.
It is our intention to facilitate the dissemination of the Berok
K4 line from P. cynomolgi, a species proven as an excellent sur-
rogate for P. vivax, so as to broaden the scope of investigations
that in vitro-cultured parasites would allow. Routine cultivation is
easily initiated from cryopreserved stocks using the conditions
and methodology that were optimised to enable robust growth
and large-scale production, should this be needed. We have
shown that in vitro-produced Berok K4 parasites are indis-
tinguishable morphologically from in vivo and ex vivo parasites,
and that they retained their infectivity to monkeys and subse-
quently to mosquitoes to generate infective sporozoites. The
presence of caveolae, and the occurrence of rosettes, provides
additional evidence that this parasite species also shares the
characteristic morphological, phenotypical and rheological
alterations observed for P. vivax-infected red blood cells.
The last 10 years have witnessed signiﬁcant successes in the
search for new antimalarial compounds, with 17 new drug can-
didates developed since 201035,36. The key contribution was the
development of a standard P. falciparum asexual blood-stage
SYBR green I proliferation assay adapted to automated screening
technologies14. Such strategies are not possible for P. vivax, and
high-throughput screening of compounds would require a pro-
hibitively large number of P. cynomolgi-infected macaques. We
validated the potential of the P. cynomolgi Berok K4 line cultures
to extend high-throughput screens to identify lead compounds
active against P. vivax. It was interesting to note that some of the
compounds from the Malaria Box and the Pathogen Box used for
the validation were inhibitory to one, but not the other of the
Fig. 3 Phenotypic and rheological characterisation of the Berok K4 line from in vitro culture. a P. cynomolgi Berok K4-infected RBCs exhibit caveolae
structures (yellow arrows) that are similar to those in P. vivax-infected RBCs (scanning electron microscopy, scale bars represent 1 µm and 100 nm for area
shown at higher magniﬁcation in white box). b An atomic force microscope scan of trophozoite-infected human blood cells revealed caveolae occurred at
lower frequency when compared with P. vivax. c, d The median (+ /- IQR) dimensions of these caveolae were similar (P. vivax n= 177, P. cynomolgi n= 91).
e, f Amnis ﬂow imaging clearly shows that the mature erythrocytic stages P. cynomolgi Berok K4; readily formed rosettes with uninfected red blood cells,
which are also a key feature P. vivax (n= 5). g, h A dual micropipette aspiration method was used to demonstrate the rheological stability of the
P. cynomolgi Berok K4 rosettes (n= 5). As observed in P. vivax, P. cynomolgi rosettes are tightly attached and the cells require around 400 pN to disrupt the
adhesion. The non-parametric data resented in b, d, f and h were analysed using the Mann–Whitney U test with the signiﬁcance level set at P < 0.05. The
histograms and lines on box plots and scatter plots represent medians, and the error bars the interquartile range (IQR)
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parasite species (P. cynomolgi and P. falciparum) used for
the validation. Thus, it is likely that activity data from P. cyno-
molgi-based screens would be a more reliable predictor of
activity against P. vivax than those that rely on P. falciparum or
on the two most often used parasites of rodents P. berghei and
P. yoelii14. Of late, various screening assays for P. vivax and
P. falciparum liver stages has been developed to evaluate novel
compounds13,37–39. Indeed, hypnozoites responsible for relapses,
a major obstacle to successful control of P. vivax, are formed by
P. cynomolgi, but not by any of the rodent parasite species.
The urgent need to ﬁnd an alternative to the anti-hypnozoitocidal
8-aminoquinoline compounds, whose potential toxicity impedes
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widespread use, led to the development of an in vitro-based
P. cynomolgi hepatic-stage assay11,12. One of the major logistical
challenges that precludes high-throughput screening is the
availability of infective sporozoites that can only be obtained from
mosquitoes fed on blood collected from P. cynomolgi-infected
macaques. The fact that the in vitro-maintained Berok K4 line
parasites retained infectiousness to mosquitoes subsequent to
cultivation augurs well for the eventual use of in vitro cultures to
support mosquito infections. We are currently exploring diverse
modiﬁcations to our culture protocols aimed at promoting
gametocytogenesis, a process known to be highly sensitive to
culture conditions, as was shown for P. falciparum40. This would
minimise non-human primate use, and substantially increase
opportunities for routine and regular sporozoite production.
Finally, it is important to point out that the P. cynomolgi model
uniquely provides the possibility to confront fundamental biolo-
gical, immunological and pathological insights, as well as ther-
apeutic approaches derived from in vitro observations with the
realities of experimental in vivo infections in the natural host. The
ability to reﬁne, or indeed to discard, a candidate compound(s) or
vaccine formulation(s) through an in vitro–in vivo ‘to-and-fro'
signiﬁcantly enhances the value of this pre-clinical model.
It is hoped that the availability of easily maintained in vitro
erythrocytic P. cynomolgi parasites could now be exploited to
conduct critical fundamental and translational research to
develop drugs and vaccines against P. vivax, a widespread species
whose control will determine the success of current efforts to
eradicate malaria.
Methods
Ethical committees and animal welfare. Macaca fascicularis (cynomolgus
monkeys) were maintained at the Novartis Laboratory Animal Services, New Jer-
sey, USA, (Novartis-LAS) and SingHealth Experimental Medicine Center, Singa-
pore. Both institutions were audited and approved by the Novartis Animal Welfare
Compliance. All animals were housed in accordance with the Guide for the Care
and Use of Laboratory Animals and the Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC) Standards. All studies were
approved by the Novartis Ethical Review Council and Novartis Institutional Ani-
mal Care and Use Committees prior (IACUC) to study initiation. In addition, work
at SingHealth was approved by the SingHealth IACUC. The BPRC is an AAALAC-
certiﬁed institute. Several rhesus macaques (M. mulatta) used in this study were
captive bred for research purposes, and were housed at the BPRC facilities under
compliance with the Dutch law on animal experiments, European directive 2010/
63/EU and with the ‘Standard for humane care and use of Laboratory Animals by
Foreign institutions’ identiﬁcation number A5539–01, provided by the Department
of Health and Human Services of the USA National Institutes of Health (NIH).
Prior to the start of experiments at BPRC, all protocols were approved by the local
independent ethical committee, according to Dutch law. Rhesus macaques were
infected with 1 × 106 P. cynomolgi Berok K4 blood-stage parasites and bled at peak
parasitaemia. About 300 female Anopheles stephensi mosquitoes Sind–Kasur strain
Nijmegen (Nijmegen University Medical Centre St Radboud, Department of
Medical Microbiology) were fed with this blood. Clinical samples utilised in this
study were collected from P. vivax-infected malaria patients attending the clinics of
the Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand, under the following
ethical guidelines in the approved protocol: OXTREC 45–09 (University of Oxford,
Centre for Clinical Vaccinology and Tropical Medicine, UK) and MUTM
2008–215 from the Ethics committee of Faculty of Tropical Medicine, Mahidol
University.
P. cynomolgi B, M and Berok strains. Three P. cynomolgi strains were used in this
study, the Berok strain41, the B strain (P. cynomolgi bastianelli)42 and M strain
(P. cynomolgi Mulligan strain)43,44. The “B” strain or P. cynomolgi bastianelli was
isolated by Garnham in 1959 from an infected M. fascicularis (previously named
M. irus) near Kuantan, in the East Coast of Malaysia42. The P. cynomolgi Berok
strain originated from Perak, Malaysia, where it was isolated from an infected
M. nemestrina monkey41. The Berok strain sample that was used to derive the
Berok K4 line consisted of a single cryopreserved 1 -mL sample passage through
Aotus monkeys and dated as 2003. The sample was thawed out as described below,
and washed prior to a tail–vein administration to a splenectomised M. fascicularis
monkey. The P. cynomolgi ‘M' strain was ﬁrst described by Mulligan in 193544, and
later shown to be transmitted to man 196143. It has been suggested that the B and
M strain isolates have been mixed-up at some time in the past, and that some of the
B and M strain aliquots in use might actually have the same parasite line3. All
strains of P. cynomolgi ultimately originated from stock collections at the CDC,
which were then since propagated in monkeys at the recipient laboratories. In this
study, the B and M strain were provided by B.R., the Berok strain cryovial used to
generate the K4 line was provided by D.E.K.
P. cynomolgi base medium composition for continuous culture. The RPMI-1640
(Roswell Park Memorial Institute) supplemented with GlutaMAX (Gibco #
61870–036) containing 30 mM HEPES (Sigma-Aldrich), 0.2% (w/v) D-glucose and
200 μM hypoxanthine (Calbiochem). In all, 20% (v/v) M. fascicularis serum (heat
inactivated) was added prior to use. The medium was ﬁlter-sterilised over 0.22 -µm
ﬁlter.
Macaque blood and serum extraction and preparation. M. fascicularis ery-
throcytes and serum were obtained from Singapore Health Services Pte Ltd. Blood
was collected by venous puncture into lithium heparin vacutainers (Becton-
Dickinson). The blood collected was adjusted to 50% haematocrit with the RPMI-
1640 supplemented with 30 mM HEPES before passing through pre-equilibrated
non-woven ﬁlters (Antoshin) to deplete leucocytes. The erythrocytes were pelleted
by centrifugation at 1800 rpm (650 rcf) for 5 min at room temperature (RT),
washed thrice in the RPMI-1640 with 30 mM HEPES and stored at 4 °C in the
same medium at 50% haematocrit until use. For collection of M. fascicularis serum,
the blood was collected by venous puncture into SST serum separation vacutainers
(Becton-Dickinson), inverted gently ﬁve times and allowed to clot in a vertical
position. The tubes were then centrifuged at 3000 rpm (1810 rcf) for 10 min at RT.
The M. fascicularis serum supernatant was collected and heat inactivated for 1 h at
56 °C and stored at −20 °C until use.
In vitro parasite growth in M. fascicularis RBCs and serum. P. cynomolgi
parasite cultures were started from 1mL of stabilate cryopreserved samples. The
frozen samples were thawed-out using the sodium chloride method45. Brieﬂy,
sequentially decreasing concentrations of NaCl were added starting with 0.2 mL of
12% (w/v) NaCl added slowly drop-wise with gentle mixing, incubated at RT for
5 min without shaking, and further diluted in 10 mL of 1.6% (w/v) NaCl added
drop-wise with gentle mixing. The samples were pelleted by centrifugation at 1800
rpm (650 rcf) for 5 min at RT, the supernatant discarded and samples were sub-
jected to a ﬁnal wash in 10 mL of 0.9% NaCl added drop-wise with gentle mixing,
pelleted by centrifugation at 1800 rpm (650 rcf) for 5 min at RT and re-suspended
in complete medium comprising P. cynomolgi base medium supplemented with
20% (v/v) macaque serum. Macaque blood was added to a 5% haematocrit. The
parasites were cultured in plates in a modiﬁed candle jar (Stemcell technologies
27310) at 37 °C comprising about 3–5% CO2, and 8–10% O246,47. Cultures were
monitored daily by Giemsa-stained thick and thin smears by microscopy and
parasitaemia adjusted between 0.5 and 5% for routine culture. The medium was
changed daily. In order to eliminate the use of the candle jar, the cultures were
adapted to trimix gas (5% CO2, 5% O2, 90% N2). All other conditions were the
same as for the modiﬁed candle jar. For culture in trimix gas, the parasites were
gassed and cultured in non-vented ﬂasks.
Parasite synchronisation. The infected RBCs from in vitro P. cynomolgi Berok K4
were ﬁrst synchronised with 5% sorbitol, and then matured to schizonts which
Fig. 4 Drug susceptibility testing using P. cynomolgi Berok K4 in vitro culture. a Correlation of P. cynomolgi Berok K4 and P. falciparum IC50 values of
common antimalarial reference compounds in a SYBR green I proliferation assay. The potency of the compounds was comparable between the two species,
except for artemisinin, atovaquone and artesunate which were more potent in P. cynomolgi as compared with P. falciparum. A X= Y line indicates equal
inhibition towards compound. b Heatmap showing IC50 (μM) of a representative set of compounds from the Malaria Box. Majority of the compounds
showed activity against both P. falciparum and P. cynomolgi, except for six compounds—MMV008127, MMV006250, MMV008270, MMV000563,
MMV007839 and MMV008294 which displayed an IC50 > 10 µM for P. cynomolgi, and < 5 µM for P. falciparum. c Heatmap showing percentage of
inhibition of the 125 antimalarial compounds from the Pathogen Box in P. cynomolgi Berok K4 and P. falciparum in different serums and concentrations. Nine
compounds (MMV676380, MMV023388, MMV026550, MMV007625, MMV023949, MMV007638, MMV676442, MMV006833 and MMV020289)
showed more than fourfold difference in inhibition between P. cynomolgi Berok K4 and P. falciparum in their equivalent serums
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were enriched using MACS LD columns (Miltenyi Biotech Asia Paciﬁc Pte Ltd.) on
magnetic sorter, where the ﬂow through containing rings and early trophozoites
were discarded. The retained late-stage parasites were eluted from the column,
washed three times with the RPMI-1640 supplemented with 30 mM HEPES and
then returned to culture.
Determination of parasitaemia via light microscopy. Thick and thin ﬁlm smears
were prepared with 5 µL of packed red blood cells for Giemsa staining, para-
sitaemia was determined from the thin ﬁlm under a light microscope with ×1000
magniﬁcations.
Transmission study from Berok K4 continuous culture. Monkey infections and
mosquito feedings were performed as previously described48. Brieﬂy, cryopreserved
in vitro-adapted P. cynomolgi Berok K4 parasites were thawed as described above,
and one million parasites were used to infect one M. mulatta monkey via intra-
venous injection, while the monkey was under ketamine sedation. Parasitaemia was
monitored through Giemsa-stained thin smears. Female An. stephensi mosquitoes
were fed with infected monkey blood using a glass feeder system on days 12 and 13
post infection, after which the monkey was cured from blood-stage parasites with
chloroquine (three daily intramuscular injections 7.5 mg/kg). Oocysts were counted
in at least ten mosquitoes at day 7 after the infected blood meal. The remaining
mosquitoes were given a second uninfected blood meal to promote sporozoite
invasion of the salivary glands.
Sporozoites from Berok K4 continuous culture. As previously described48,
sporozoites were isolated from salivary glands of infected An. stephensi mosquitoes
18 days post-infected blood meal.
Infectivity of Berok K4 sporozoites from continuous culture. M. mulatta
hepatocytes from different donors were isolated as previously described48, and then
seeded onto collagen-coated 384-well plates at a density of 28,000 hepatocytes/well
in William’s B medium as previously described48. Two days later, 20,000 spor-
ozoites were added to each well. Infections were carried out in six replicates per
experimental condition. Daily medium refreshments were performed, and the
infected cells were ﬁxed in 4% PFA after 6 days of sporozoite infection. Parasites
were immunostained with anti-PcHsp70 antibodies and goat-anti-rabbit Alexa 568
red secondary antibodies (Invitrogen A11011), while the nuclei were stained with
DAPI before they were visualised using the Operetta high content screening
automated microscope. Image analysis was done using the analysis algorithm as
designed in previous study48 with a minor adaptation for the change in ﬂuorescent
label of the secondary antibody.
Micropipette aspiration and RBC sphericity measurement. The micropipette
aspiration technique was modiﬁed from Hochmuth, 200049. Brieﬂy, 1 µL of packed
red blood cells containing ~1% parasitaemia and suspended in 1 mL of PBS
(1% BSA). The samples were mounted onto the Olympus IX71 Inverted Micro-
scope. A borosilicate glass micropipette (~1.5 -µm inner diameter) was used to
extract the cell membrane under a negative pressure at a pressure drop rate of
0.5 pa/s. The corresponding cell membrane deformation was monitored using
a ×100 oil immersion lens. The cell membrane deformation was recorded using
the QColor5 High Resolution Color CCD Digital Fire Wire Camera (Olympus)
and processed by QCapture Pro 6.0 (Olympus). The cell membrane shear modulus
was calculated using the hemispherical cap model49. To quantify the binding
force between uninfected red cells and a iRBC (rosetting cells), a double-pipette
aspiration method was used50. A rosette was held by a micropipette (diameter=
2.0 ± 0.2 µm). A second micropipette was used to aspirate the uninfected red cell at
increased levels of pressure. The force (F) to detach the red cell from the iRBC was
calculated as F= πr2 × P, where r is the inner diameter of the second micropipette,
and P is the pressure required for cell detachment. The aspiration pressure was
measured by a pressure transducer (P61 model, Validyne Engineering), and
recorded by USB-COM Data logger (Validyne Engineering). The process was
recorded using a Dual CCD Digital Camera DP80 (Olympus®) at one frame/s.
Recorded images were analysed with CellSens Dimension (Olympus®).
Atomic force microscopy. Infected RBCs (iRBCs) were harvested at the tropho-
zoite stage and processed as follows: 200 µl of blood media mixture were supra-
vitally stained with 1 µL of DAPI for 15 min in an incubator and prepared as
smears (unﬁxed and air dried) for Atomic Force Microscopy (AFM). At least
20 iRBCs from each isolate and cell type was scanned using AFM. The total area
analysed per parasite was 15 µm2 (n= 15 for each respective group, of 1 µm2 area/
infected red cell). We were able to conduct serial measurements (with AFM, then
and with Giemsa) by using a copper microdisk grid (H7 ﬁnder grid, SPI Supplies,
PA) attached underneath the glass slide allowing us to locate and image the same
cell. These thin smears were ﬁrst AFM scanned by a Dimension 3100 model with a
Nanoscope IIIa controller (Veeco, Santa Barbara, CA) using the tapping mode. The
probes used for imaging were 125 -µm long by 30 -µm wide single-beam shaped
cantilevers (Model PPP-NCHR-50, Nanosensors) with tip radius of curvature of
5–7 nm. Images were processed using the Nanoscope 5.30 software (Veeco, Santa
Barbara, CA).
Electron microscopy. Sorted cells coated on poly-lysine (Sigma) glass coverslips
were ﬁxed in 2.5% glutaraldehyde, washed and treated with 1% osmium tetroxide
(Ted Pella Inc.) before critical point drying (CPD 030, Bal-Tec). Glass coverslips
were sputter coated with gold in a high vacuum (SCD005 sputter coater, Bal-Tec)
and imaged with a ﬁeld-emission scanning electron microscope (JSM-6701F,
JEOL) at an acceleration voltage of 8 kV51.
Image stream analysis of resetting. We determined the percentage of rosetting
of P. cynomolgi iRBC by image stream analysis using a method adapted from Lee
et al.52. Brieﬂy, iRBCs stained with Hoechst and dihydroethidium were suspended
in PBS to a haematocrit of 2% were assayed with the ImageStream 100 (Amnis,
Seattle, WA) ﬁtted with a ×60 objective. At least 200 untreated parasites for each
single-stain condition were used to create a compensation matrix. During
screening, 10,000 parasites were acquired and gated using the technique adopted
from Malleret et al.53 along with the added selection of cells that were not singlets
(one or more cells adhering to an infected cell staining positive for Hoechst).
Analysis was performed with the IDEAS software (version 4.0).
DNA extraction, PCR ampliﬁcations and sequencing. As described previously54,
the DNA was extracted, and the genes rbp1b, rbp2a and rbp2b were compared
between the P. cynomolgi Berok, P. cynomolgi B strain and P. cynomolgi M strain.
Compound libraries. The Pathogen Box (http://www.pathogenbox.org/), modelled
after the Malaria Box55, is an open-source library comprising of 400 diverse open-
source compounds targeting against neglected tropical diseases. The Malaria Box
was an open-source library (until December 2015), which comprised 400 diverse
compounds with antimalarial activity. In addition, the three drug candidates (the
phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor KDU69156, the imidazolo-
piperazines KAF17957 and the spiroindolone KAF24658) were included as addi-
tional controls.
Compound plate preparation. Test compounds were prepared by serially diluting
a 10 mM compound stock threefold with DMSO for eight concentration points in
the master compound plate. In all, 100% DMSO was used as the negative control,
and 10 mM meﬂoquine was used as the positive control. A 1000-fold dilution
(either 100 nL or 50 nL) of compound from the master plate were spotted onto a
96-well or 384-well assay plate, respectively using Mosquito® nanoliter dispenser
(Cambridge, UK). The plates were then sealed with a removable foil seal using
PlateLoc Thermal Microplate Sealer (Agilent) until use.
In vitro high-throughput IC50 drug susceptibility assay. There are various high-
throughput screens based on cultured P. falciparum25,59–63 or on the hepatic stages
of the rodent parasites P. berghei or P. yoelii57,61 described. Here, we adapt the
SYBR green I proliferation assay as described by Plouffe et al. Brieﬂy, 50 µL of the
P. cynomolgi culture were dispensed manually into the 384-well plate at both ﬁnal
parasitaemia of 0.5% (for dose response assay) or 1% (for single point assay) and
the haematocrit adjusted to 2.5%. The 384-well assay plates were incubated at 37 °C
for 72 h in 5% CO2, 5% O2 and 90% N2. After a 72 h incubation, 10 µL of lysis
buffer, consisting of 5 mM EDTA, 20 mM Tris-HCI pH 7.5, 1.6% Triton X-100 and
0.16% Saponin, were added to each well, and the plate was incubated in the dark
for 24 h at RT. The plate was read for ﬂuorescence using BioTek Synergy™ 4 hybrid
microplate reader (Vermont, USA) using a bottom read mode at excitation
wavelength of 485 nm and emission wavelength of 528 nm.
Robustness of in vitro IC50 drug susceptibility assay. The quality of the assay
was determined with the Z’ value64, which takes into account the signal dynamic
range and the data variation associated with the signal measurements and is cal-
culated as follow: Z’= 1 – ((3 SD of positive control+ 3 SD of negative control)/
(average of positive control–average of negative control)). An assay with Z’ ≥ 0.5 <
1 is considered robust. Three repeats were carried out from which the Z’ values
showed the robustness of the assay. Read ﬂuorescence (bottom read), λex=
485 nm. λem= 528 nm. Fluorescence values were normalised based on maximum
ﬂuorescence signal values for DMSO-treated wells and the minimum ﬂuorescence
signal values for wells containing the highest concentration of negative control
compound, 10 µM meﬂoquine.
Schizont maturation assay using ﬂow-cytometry analysis. The maturation
assay for P. vivax was carried out as described previously65,66, while parasite
growth was assessed by ﬂow cytometry53 (Fig. 5a). In all, 200 μL of tightly syn-
chronised ring-stage culture of P. cynomolgi was dispensed manually in the 96-well
compound plate at a ﬁnal parasitaemia of 0.5% and haematocrit adjusted to 2%.
The assay plates were incubated at 37 °C for around 44 h in 5% CO2, 5% O2 and
90% N2 until mid-late schizonts stage (> 5 merozoites) was observed in the drug-
free control wells via Giemsa staining. Each well was well mixed, and 20 µL was
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harvested into a small curved-bottom tube (Micronic) before 0.5 μL of 1 mg/mL
dihydroethidium (Sigma) and 1 μL of 800 μM of Hoechst 33342 (Sigma) was added
and made up to 100 μL with PBS. The tubes were incubated at RT for 20 min, and
100,000 events were acquired with an Accuri C6 (BD Biosciences, USA). The data
were analysed using FlowJo software (Tree Star Inc.).
Statistical analysis. The parametric data presented in Fig. 2c, d were analysed
using the Welch’s t test with the signiﬁcance level set at P < 0.05. The histograms
represent means, and the error bars the standard deviation (SD). The non-
parametric data (all data sets failed the D’Agostino & Pearson normality test)
presented in Fig. 3b, d, f and h and Fig. 5d were analysed using the Mann–Whitney
U test with the signiﬁcance level set at P < 0.05. The histograms and lines on box
plots and scatter plots represent medians and the error bars the interquartile range
(IQR). All analyses were carried out using GraphPad Prism™ 7 for windows
(GraphPad Software Inc, USA).
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
The source data underlying Figs. 1b, 1c, 2c, 2d, 3a-h, 4a-c, 5b-d, Supplementary Figs. 1
and 4 are provided as a Source Data ﬁle. Any additional data that support the ﬁndings of
this study may be requested from the corresponding authors.
Received: 22 October 2018 Accepted: 28 June 2019
References
1. Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture.
Science 193, 673–675 (1976).
2. World Health Organization. World Malaria Report 2016 (World Health
Organization, Geneva, 2016).
3. Tachibana, S. et al. Plasmodium cynomolgi genome sequences provide insight
into Plasmodium vivax and the monkey malaria clade. Nat. Genet. 44,
1051–1055 (2012).
4. Pasini, E. M. et al. An improved Plasmodium cynomolgi genome assembly
reveals an unexpected methyltransferase gene expansion. Wellcome Open Res.
2, 42 (2017).
5. Shortt, H. E. & Garnham, P. C. Demonstration of a persisting exo-erythrocytic
cycle in Plasmodium cynomolgi and its bearing on the production of relapses.
Br. Med J. 1, 1225–1228 (1948).
6. Krotoski, W. A. et al. Observations on early and late post-sporozoite tissue
stages in primate malaria. II. The hypnozoite of Plasmodium cynomolgi
bastianellii from 3 to 105 days after infection, and detection of 36- to 40-hour
pre-erythrocytic forms. Am. J. Trop. Med. Hyg. 31, 211–225 (1982).
7. Krotoski, W. A. et al. Observations on early and late post-sporozoite tissue
stages in primate malaria. I. Discovery of a new latent form of Plasmodium
cynomolgi (the hypnozoite), and failure to detect hepatic forms within the ﬁrst
24 hours after infection. Am. J. Trop. Med. Hyg. 31, 24–35 (1982).
8. Schmidt, L. H. et al. Plasmodium cynomolgi infections in the rhesus monkey.
Am. J. Trop. Med. Hyg. 31, 609–703 (1982).
9. Deye, G. A. et al. Use of a rhesus Plasmodium cynomolgi model to screen for
anti-hypnozoite activity of pharmaceutical substances. Am. J. Trop. Med. Hyg.
86, 931–935 (2012).
10. DiTusa, C. et al. Causal prophylactic efﬁcacy of primaquine, tafenoquine, and
atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey
model. J. Parasitol. 100, 671–673 (2014).
11. Dembele, L. et al. Towards an in vitro model of Plasmodium hypnozoites
suitable for drug discovery. PloS ONE 6, e18162 (2011).
12. Dembele, L. et al. Persistence and activation of malaria hypnozoites in long-
term primary hepatocyte cultures. Nat. Med. 20, 307–312 (2014).
13. March, S. et al. A microscale human liver platform that supports the hepatic
stages of Plasmodium falciparum and vivax. Cell Host Microbe. 14, 104–115
(2013).
14. Hovlid, M. L. & Winzeler, E. A. Phenotypic screens in antimalarial drug
discovery. Trends Parasitol. 32, 697–707 (2016).
15. Nguyen-Dinh, P., Gardner, A. L., Campbell, C. C., Skinner, J. C. & Collins, W.
E. Cultivation in vitro of the vivax-type malaria parasite Plasmodium
cynomolgi. Science 212, 1146–1148 (1981).
16. Zhou, Z. X., Li, G. R., Ye, J. S., Xi, Y. H. & Huang, R. Z. Continuous in vitro
cultivation of erythrocytic Plasmodium cynomolgi. Chin. Med. J 97, 84–88
(1984).
17. Sutton, P. L. et al. Characterizing the genetic diversity of the monkey malaria
parasite Plasmodium cynomolgi. Infect., Genet. Evol.: J. Mol. Epidemiol. Evolut.
Genet. Infect. Dis. 40, 243–252 (2016).
18. Okenu, D. M. et al. The reticulocyte binding proteins of Plasmodium
cynomolgi: a model system for studies of P. vivax. Mol. Biochem. Parasitol.
143, 116–120 (2005).
19. Galinski, M. R., Medina, C. C., Ingravallo, P. & Barnwell, J. W. A reticulocyte-
binding protein complex of Plasmodium vivax merozoites. Cell 69, 1213–1226
(1992).
20. Zeeman, A. M. et al. PI4 kinase is a prophylactic but not radical curative target
in Plasmodium vivax-type malaria parasites. Antimicrob. Agents Chemother.
60, 2858–2863 (2016).
21. Akinyi, S. et al. A 95 kDa protein of Plasmodium vivax and P. cynomolgi
visualized by three-dimensional tomography in the caveola-vesicle complexes
(Schuffner’s dots) of infected erythrocytes is a member of the PHIST family.
Mol. Microbiol. 84, 816–831 (2012).
22. Lee, W. C. et al. Glycophorin C (CD236R) mediates vivax malaria parasite
rosetting to normocytes. Blood 123, e100–e109 (2014).
23. Russell, B. M. & Cooke, B. M. The rheopathobiology of Plasmodium vivax and
other important primate malaria parasites. Trends Parasitol. 33, 321–334
(2017).
24. Zhang, R. et al. A basis for rapid clearance of circulating ring-stage malaria
parasites by the spiroindolone KAE609. J. Infect. Dis. 213, 100–104 (2016).
25. Plouffe, D. et al. In silico activity proﬁling reveals the mechanism of action of
antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci.
USA 105, 9059–9064 (2008).
26. White, N. J. et al. Antimalarial activity of KAF156 in falciparum and vivax
malaria. New Engl. J. Med. 375, 1152–1160 (2016).
27. Olliaro, P. L. et al. Implications of Plasmodium vivax biology for control,
elimination, and research. Am. J. Trop. Med. Hyg. 95, 4–14 (2016).
28. Bass, C. C. & Johns, F. M. The cultivation of malarial Plasmodia (Plasmodium
vivax and Plasmodium falciparum) in vitro. J. Exp. Med. 16, 567–579 (1912).
29. Haynes, J. D., Diggs, C. L., Hines, F. A. & Desjardins, R. E. Culture of human
malaria parasites Plasmodium falciparum. Nature 263, 767–769 (1976).
30. Trigg, P. I. Recent advances in malaria parasite cultivation and their
application to studies on host-parasite relationships: a review. Bull. World
Health Organ. 63, 387–398 (1985).
31. Kocken, C. H. et al. Plasmodium knowlesi provides a rapid in vitro and
transfection system that enables double-crossover gene knockout studies.
Infect. Immun. 70, 655–660 (2002).
32. Moon, R. W. et al. Adaptation of the genetically tractable malaria pathogen
Plasmodium knowlesi to continuous culture in human erythrocytes. Proc. Natl
Acad. Sci. USA 110, 531–536 (2013).
33. Kosaisavee, V. et al. Strict tropism for CD71(+)/CD234(+) human
reticulocytes limits the zoonotic potential of Plasmodium cynomolgi. Blood
130, 1357–1363 (2017).
34. Collins, W. E., Warren, M. & Galland, G. G. Studies on infections with the
Berok strain of Plasmodium cynomolgi in monkeys and mosquitoes. J.
Parasitol. 85, 268–272 (1999).
35. Wells, T. N., Hooft van Huijsduijnen, R. & Van Voorhis, W. C. Malaria
medicines: a glass half full? Nat. Rev. Drug Discov. 14, 424–442 (2015).
36. Phillips, M. A. et al. Malaria. Nat. Rev. Dis. Prim. 3, 17050 (2017).
37. Roth, A. et al. A comprehensive model for assessment of liver stage therapies
targeting Plasmodium vivax and Plasmodium falciparum. Nat. Commun. 9,
1837 (2018).
38. Khetani, S. R. & Bhatia, S. N. Microscale culture of human liver cells for drug
development. Nat. Biotechnol. 26, 120–126 (2008).
39. March, S. et al. Micropatterned coculture of primary human hepatocytes and
supportive cells for the study of hepatotropic pathogens. Nat. Protoc. 10,
2027–2053 (2015).
40. Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum
gametocytes to mosquitoes. Parasitology 98(Pt 2), 165–173 (1989).
41. Bennett, G. F., Warren, M. & Cheong, W. H. Biology of the simian malarias of
southeast Asia. II. The susceptibility of some Malaysian mosquitoes to
infection with ﬁve strains of Plasmodium cynomolgi. J. Parasitol. 52, 625–631
(1966).
42. Garnham, P. C. A new subspecies of Plasmodium cynomolgi. Rivista Di
Parassitologia 20, 273–278 (1959).
43. Coatney, G. R. et al. Transmission of the M strain of Plasmodium cynomolgi to
man. Am. J. Trop. Med. Hyg. 10, 673–678 (1961).
44. Mulligan, H. W. Descriptions of two species of monkey Plasmodium isolated
from Silenus irus. Arch. f. Protist 84, 285–314 (1935).
45. Moll, K., Ljungström, I., Perlmann, H., Scherf, A. & Wahlgren M. Methods In
Malaria Research 5th edn (BioMalPar, Manassas, VA, 2008).
46. Emerson R. & Held, A. A. Aqualinderella fermentans gen. et sp. n., a
phycomycete adapted to stagnant waters. II. isolation, cultural characteristics,
and gas relations. Am. J. Bot. 56, 1103-1120 (1969).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11332-4
12 NATURE COMMUNICATIONS |         (2019) 10:3635 | https://doi.org/10.1038/s41467-019-11332-4 | www.nature.com/naturecommunications
47. Schuster, F. L. Cultivation of Plasmodium spp. Clin. Microbiol. Rev. 15,
355–364 (2002).
48. Zeeman, A. M. et al. KAI407, a potent non-8-aminoquinoline compound that
kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.
Antimicrob. Agents Chemother. 58, 1586–1595 (2014).
49. Hochmuth, R. M. Micropipette aspiration of living cells. J. Biomech. 33, 15–22
(2000).
50. Nash, G. B., Cooke, B. M., Carlson, J. & Wahlgren, M. Rheological properties
of rosettes formed by red blood cells parasitized by Plasmodium falciparum.
Br. J. Haematol. 82, 757–763 (1992).
51. Malleret, B. et al. Signiﬁcant biochemical, biophysical and metabolic diversity
in circulating human cord blood reticulocytes. PloS ONE 8, e76062 (2013).
52. Lee, Y. Q. et al. A high-content phenotypic screen reveals the disruptive
potency of quinacrine and 3’,4’-dichlorobenzamil on the digestive vacuole of
Plasmodium falciparum. Antimicrob. Agents Chemother. 58, 550–558 (2014).
53. Malleret, B. et al. A rapid and robust tri-color ﬂow cytometry assay for
monitoring malaria parasite development. Sci. Rep. 1, 118 (2011).
54. Lim, M. Y. X. et al. UDP-galactose and acetyl-coA transporters as Plasmodium
multidrug resistance genes. Nat. Microbiol. 1, 161–166 (2016).
55. Spangenberg, T. et al. The open access malaria box: a drug discovery catalyst
for neglected diseases. PloS ONE 8, e62906 (2013).
56. McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria.
Nature 504, 248–253 (2013).
57. Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation
antimalarial drug discovery. Science 334, 1372–1377 (2011).
58. Rottmann, M. et al. Spiroindolones, a potent compound class for the
treatment of malaria. Science 329, 1175–1180 (2010).
59. Swann, J. et al. High-throughput luciferase-based assay for the discovery of
therapeutics that prevent malaria. ACS Infect. Dis. 2, 281–293 (2016).
60. Plouffe, D. M. et al. High-throughput assay and discovery of small molecules
that interrupt malaria transmission. Cell Host Microbe. 19, 114–126 (2016).
61. Gamo, F. J. et al. Thousands of chemical starting points for antimalarial lead
identiﬁcation. Nature 465, 305–310 (2010).
62. Baragana, B. et al. A novel multiple-stage antimalarial agent that inhibits
protein synthesis. Nature 522, 315–320 (2015).
63. Avery, V. M. et al. Screening and hit evaluation of a chemical library against
blood-stage Plasmodium falciparum. Malar. J 13, 190 (2014).
64. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter
for use in evaluation and validation of high throughput screening assays. J.
Biomol. Screen 4, 67–73 (1999).
65. Sharrock, W. W. et al. Plasmodium vivax trophozoites insensitive to
chloroquine. Malar. J 7, 94 (2008).
66. Russell, B. et al. Determinants of in vitro drug susceptibility testing of
Plasmodium vivax. Antimicrob. Agents Chemother. 52, 1040–1045 (2008).
Acknowledgements
We thank the Medicines for Malaria Venture (MMV, Switzerland) for providing the
Pathogen Box compounds and accompanying information. We also thank John Ferretti
and Nicole Ecklof for their support with the Macaca fascicularis work in Novartis
Laboratory Animal Services, New Jersey, USA. The Novartis Institute Tropical Diseases
(NITD), Singapore and the University of Otago, New Zealand co-ﬁnanced the
project. B.R. was jointly funded by the Royal Society New Zealand Marsden Fund
(UOO1710) and the Health Research Council of New Zealand e-ASIA Joint Research
Program (17/678). P.B. was partly supported by the National University of Singapore
Start-up funds. L.R. was partly supported by a grant from the National Medical Research
Council (#OFIRG17Nov123). IDMIT (G.S., ND-B, RLG) infrastructure is supported by
the French government Programme d’Investissements d’Avenir (PIA), under grant ANR-
11-INBS-0008 (INBS IDMIT). G.S. was supported by a grant from the Agence Nationale
de la Recherche, France (ANR-17-CE13-0025-01). D.K. was supported by a grant from
MMV (MMV RD/16/1082). SMRU is part of the Mahidol Oxford University Research
Unit, supported by the Wellcome Trust of Great Britain.
Author contributions
A.C.Y.C., D.E.K., B.R. and P.B. designed the project and experiments. A.C.Y.C., J.J.Y.O.,
R.S., V.K., B.M., A.M.Z., C.A.C, A.E., C.J.J, R.Z., B.H.T., S.N.A., A.Y., S.P.M, M.R.G,
J.S.C., K.S.W.T., K.B., S.B., A.L., F.N., C.B., B.K.S.Y., D.M., N.D-B., R.L.G., G.S., B.R. and
P.B. developed and performed the experiments, as well as analysed the data. A.C.Y.C.,
D.E.K., B.K.S.Y., C.H.M.K., L.R., T.T.D., G.S., B.R. and P.B. developed and designed the
concept and provided resources. A.C.Y.C., B.R., G.S. and P.B. wrote the paper, and all
authors reviewed and edited the paper.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-11332-4.
Competing interests: A.C.Y.C., J.J.Y.O., B.H.T., S.N.A., A.Y., K.B., S.B., A.L., C.B., B.K.S.Y.,
T.T.D. and P.B were/are employed by and/or shareholders of Novartis Pharma AG. The
remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11332-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3635 | https://doi.org/10.1038/s41467-019-11332-4 | www.nature.com/naturecommunications 13
SUPPLEMENTARY INFORMATION
Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages 1 
Adeline C.Y. Chua1,2,3§, Jessica Jie Ying Ong2,3§, Benoit Malleret1,4, Rossarin Suwanarusk1,2, Varakorn 2 
Kosaisavee4,5, Anne-Marie Zeeman6, Caitlin A. Cooper7, Kevin S.W. Tan4, Rou Zhang4, Bee Huat Tan3, 3 
Siti Nurdiana Abas3, Andy Yip3, Anne Elliot7, Chester J. Joyner8,10, Jee Sun Cho4, Kate Breyer11, Szczepan 4 
Baran11, Amber Lange11, Steven P. Maher7, François Nosten12,13, Christophe Bodenreider3, Bryan K. S. 5 
Yeung3, Dominique Mazier14,15, Mary R. Galinski9,10, Nathalie Dereuddre-Bosquet15, Roger Le Grand15, 6 
Clemens H. M. Kocken6, Laurent Rénia1,4, Dennis E. Kyle7, Thierry T. Diagana3, Georges Snounou14,15,16, 7 
Bruce Russell2,4*, Pablo Bifani1, 3,4,17*  8 
1 Singapore Immunology Network, A*STAR, 138648 Singapore 9 
2 Department of Microbiology and Immunology, University of Otago, Dunedin 9054, New Zealand  10 
3 Novartis Institute for Tropical Diseases, 138670 Singapore 11 
4 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University 12 
of Singapore, 119077 Singapore  13 
5 Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, 14 
Thailand 15 
6 Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands  16 
7 Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, USA 17 
8 Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University, Atlanta, GA USA 18 
9 Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, GA, USA 19 
10 Emory Vaccine Center, Emory University, Atlanta, GA, USA 20 
11 Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East 21 
Hanover, NJ 07936-1080, USA  22 
12 Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical 23 
Medicine, Mahidol University, Mae Sot, Thailand 24 
13 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research 25 
Building, , University of Oxford Old Road Campus, OxfordUnited Kingdom  26 
14 Sorbonne Universités, Université Pierre et Marie Curie, UMR S945 Paris, France  27 
15 Centre d'Immunologie et de Maladies Infectieuses-Paris, INSERM U1135, Centre National de la 28 
Recherche Scientifique, Paris, France 29 
16 CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune 30 
Diseases (IMVA), IDMIT Department, IBJF, DRF, Fontenay-aux-Roses, France 31 
17 Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, 32 
London, London WC1E 7HT, United Kingdom 33 
 34 
§Equal contributions  35 
*Correspondence: BR: b.russell@otago.ac.nz or PB: micpb@nus.edu.sg   36 

Supplementary Figure 2
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Supplementary Figure 2. Measurement of the diameter of the caveolae structures observed on the surface of the
infected red blood cells of the continuous culture of P. cynomolgi Berok K4 strain by atomic force microscopy.
0.0
0.2
0.4
0.6
0.8
1.0
N
/R
Z
'
10mM (P1) 10mM (P2) 1mM (P1)
1mM (P2)
P. cynomolgi (R1)
P. cynomolgi (R2)
P. cynomolgi
P. falciparum
P. falciparum (R2)
P. falciparum (R3)
0.0
0.2
0.4
0.6
0.8
1.0
N
/R
Z
'
10mM (P1) 10mM (P2) 1mM (P1)
1mM (P2)
P. cynomolgi (R1)
P. cynomolgi (R2)
P. cynomolgi
P. falciparum
P. falciparum (R2)
P. falciparum (R3)
Supplementary Figure 3
Supplementary Figure 3. The robustness (Z’ value) of the adapted SYBR green I proliferation assay for the continuous 
culture of P. cynomolgi Berok K4 strain was similar to the SYBR green I proliferation assay routinely used  for P. 
falciparum.

